Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (880)	3/21/2000 9:27:00 AM
From: scaram(o)uche	Respond to of 52153

>> Most people would single out the wild run-up / run-down of genomic stocks as the biggest excess of the biotech fever. And yet it's interesting that it took this craziness to get Incyte a reasonable valuation relative to its peers. << Glad someone caught it. When I made the prediction, there had been months of INCY-bad mouthing. Newbies to the sector, and those who had been immersed in LG*D bullshit for years, were shocked. Now, nobody will blink an eye. Perceptions change rapidly for the sector. Take them to the bank.